Starting in the fall of 2023, its rapid-acting injectable insulin Humalog will drop from $274.70 to $66.40 (from €258 to €62.30) per 10-milliliter vial.
In a rare decision for the pharmaceutical industry, the American company Eli Lilly, one of the world's leading manufacturers of anti-diabetic drugs, announced on Wednesday, March 1, that it would reduce the price of its most commonly prescribed insulins by 70% in the United States. Subscribers only Attorney and activist Emmabella Rudd at a prescription drug price protest in Washington, D.C., on October 6, 2022. The American company Eli Lilly has decided to significantly reduce the price of its insulins for diabetes patientsīy Zeliha Chaffin Published on March 8, 2023, at 9:45 am (Paris) In the US, pressure is mounting for Big Pharma
